HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Czech mass methanol outbreak 2012: epidemiology, challenges and clinical features.

AbstractOBJECTIVES:
Methanol poisonings occur frequently globally, but reports of larger outbreaks where complete clinical and laboratory data are reported remain scarce. The objective of the present study was to report the data from the mass methanol poisoning in the Czech Republic in 2012 addressing the general epidemiology, treatment, and outcomes, and to present a protocol for the use of fomepizole ensuring that the antidote was provided to the most severely poisoned patients in the critical phase.
METHODS:
A combined prospective and retrospective case series study of 121 patients with confirmed methanol poisoning.
RESULTS:
From a total of 121 intoxicated subjects, 20 died outside the hospital and 101 were hospitalized. Among them, 60 survived without, and 20 with visual/CNS sequelae, whereas 21 patients died. The total and hospital mortality rates were 34% and 21%, respectively. Multivariate regression analysis found pH < 7.0 (OR 0.04 (0.01-0.16), p < 0.001), negative serum ethanol (OR 0.08 (0.02-0.37), p < 0.001), and coma on admission (OR 29.4 (10.2-84.6), p < 0.001) to be the only independent parameters predicting death. Continuous hemodialysis was used more often than intermittent hemodialysis, but there was no significant difference in mortality rate between the two [29% (n = 45) vs 17% (n = 30), p = 0.23]. Due to limited stockpiles of fomepizole, ethanol was administered more often; no difference in mortality rate was found between the two [16% (n = 70) vs. 24% (n = 21), p = 0.39]. The effect of folate administration both on the mortality rate and on the probability of visual sequelae was not significant (both p > 0.05).
CONCLUSIONS:
Severity of metabolic acidosis, state of consciousness, and serum ethanol on admission were the only significant parameters associated with mortality. The type of dialysis or antidote did not appear to affect mortality. Recommendations that were issued for hospital triage of fomepizole administration allowed conservation of valuable antidote in this massive poisoning outbreak for those patients most in need.
AuthorsSergey Zakharov, Daniela Pelclova, Pavel Urban, Tomas Navratil, Pavel Diblik, Pavel Kuthan, Jaroslav A Hubacek, Michal Miovsky, Jiri Klempir, Manuela Vaneckova, Zdenek Seidl, Alexander Pilin, Zdenka Fenclova, Vit Petrik, Katerina Kotikova, Olga Nurieva, Petr Ridzon, Jan Rulisek, Martin Komarc, Knut Erik Hovda
JournalClinical toxicology (Philadelphia, Pa.) (Clin Toxicol (Phila)) Vol. 52 Issue 10 Pg. 1013-24 (Dec 2014) ISSN: 1556-9519 [Electronic] England
PMID25345388 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antidotes
  • Biomarkers
  • Pyrazoles
  • Ethanol
  • Fomepizole
  • Methanol
Topics
  • Acidosis (chemically induced, epidemiology, therapy)
  • Adolescent
  • Adult
  • Aged
  • Antidotes (therapeutic use)
  • Biomarkers (blood)
  • Consciousness
  • Czech Republic (epidemiology)
  • Disease Outbreaks
  • Drug Overdose (blood, diagnosis, epidemiology, mortality, therapy)
  • Ethanol (blood)
  • Female
  • Fomepizole
  • Hospital Mortality
  • Hospitalization
  • Humans
  • Logistic Models
  • Male
  • Mass Casualty Incidents
  • Methanol (blood, pharmacokinetics, poisoning)
  • Middle Aged
  • Multivariate Analysis
  • Odds Ratio
  • Prospective Studies
  • Pyrazoles (therapeutic use)
  • Renal Dialysis
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome
  • Vision Disorders (chemically induced, epidemiology, therapy)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: